WVE News and Press, Wave Life Sciences Ltd. From 09/12/23

2023-09-12 17:09:48 ET Summary Wave Life Sciences Ltd. develops stereopure oligonucleotides targeting disease-causing genetic mutations. The company has lead assets in phase 1/2 trials for Duchenne muscular dystrophy and Huntington's Disease. Wave has collaborations with GSK a...

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Off...

WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (AAT) protein and reduce levels of mutant Z-AAT protein, thereby addressing alpha-1 antitrypsin deficiency-related lung di...

2023-08-17 06:40:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks aren’t for everyone. But if you want to dive into a sector that can potentially give you incredible returns, you’ll want to focus your search on A-rated biotech...

2023-08-06 03:14:05 ET Wave Life Sciences Ltd. (WVE) Q2 2023 Earnings Conference Call Aug 3, 2023 8:30 AM ET Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President and Chief Executive Officer Anne Cheung - Chief Development Officer ...

2023-08-03 08:03:45 ET Wave Life Sciences press release ( NASDAQ: WVE ): Q2 GAAP EPS of -$0.20 beats by $0.13 . Revenue of $22.1M (+5873.0% Y/Y) beats by $14.16M . Shares +2% PM. Cash and cash equivalents of $173.0 million as of June 30, 2023, with runw...

Preparing for imminent submission of clinical trial applications (CTAs) for GalNAc-conjugated AATD candidate (WVE-006), the industry’s first RNA editing clinical candidate Novel DMD therapeutic candidate (WVE-N531) with best-in-class exon skipping clinical data is on track to e...

2023-08-02 14:25:13 ET Wave Life Sciences ( NASDAQ: WVE ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$0.35 (+43.5% Y/Y) and the consensus Revenue Estimate is $7.94M vs $0.37M in 2Q22. Over th...

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, Au...

2023-06-26 08:58:49 ET Wave Life Sciences ( NASDAQ: WVE ) said on Monday that it had joined the Russell 2000 and Russell 3000 indexes as a part of the annual reconstitution, effective after the U.S. market opens on June 26. Press Release For further details...